Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study the investigators are going to evaluate the efficacy pentoxifyline in HTLV-1 patients with neurological diseases: HAM/TSP or neurogenic bladder. In some laboratory experiments the investigators observed that this drug had the capacity to reduce the immune response in HTLV-1 infected cells. Since the exacerbated immune response is know to cause neurological disease in patients with HTLV-1 the investigators hope that pentoxifyline can alleviate symptoms and delay the progress of HAM/TSP in patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitário Professor Edgard Santos
• Treatments: Pentoxifylline

Criteria

Inclusion Criteria:

• Age ≥ 18 and ≤ 80 years;

• Confirmed HTLV-1 infection with Western Blot analysis;

• HAM/TSP diagnosed patients according to the WHO

• Patients with HTLV-1 and neurogenic bladder diagnosed by clinical and urodynamic study

• Disease duration < 5 years

Exclusion Criteria:

• Neurological diseases with functional limitations.

• Co-infection with Hepatitis B or C, Syphilis, Chagas Disease or HIV

• Use of immunossupressive drugs

• Immune disease

• Pregnancy